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Abstract: Small cell lung cancer (SCLC) is one of many types rapidly growing malignant diseases, such as Burkitt’s lymphoma and 
  testicular germ cell cancers. At present, there is no reliable way to screen for SCLC, and imaging modalities tend to be delayed in 
­ detecting­this­type­of­cancer.­The­clinical­presentation­of­acutely­and­rapidly­growing­SCLC­can­mimic­those­of­pulmonary­­ inflammatory­
or infectious disorders, and in some instances, this delays appropriate management and negatively affects patient outcome.
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Introduction
Lung cancer is the leading cause of cancer deaths 
in the United States among both men and women.1 
Among various types of cancers, small cell lung can-
cer (SCLC) carries the worst outcomes, and accounts 
for 10%–20% of all bronchogenic carcinomas in the 
United States.2,3 Since its early description as “the 
oat-cell carcinoma of the mediastinum,” the fatality 
of SCLC has not changed considerably,4 and early 
diagnosis and initiation of treatment for lung cancer 
remains a considerable problem plaguing medicine 
today. SCLC continues to carry a grim prognosis, with 
median survival of approximately 2–4 months when 
untreated, and a 5-year survival rate in the range of 
4%–5% when treated.3,5
In view of the high mortality associated with this 
disease, it may be time to examine other ways to detect 
SCLC in its earlier stages, which will likely result in 
more favorable outcomes. Given the rapid doubling 
time, SCLC may present as an acute syndrome that has 
a decent potential of being misdiagnosed as an infec-
tious­or­inflammatory­condition.­Whether­this­clinical­
scenario­has­a­significant­impact­on­patient­outcomes­
is yet to be determined, but will probably delay the 
prompt  administration  of  chemotherapy,  which  is 
shown to improve survival in all stages of SCLC.
Methods
A PubMed and Google search was performed and 
22 articles were found to be relevant to our topic and 
were­therefore­included­in­this­review.­We­also­briefly­
described a case example of rapidly growing SCLC.
Results
Various imaging modalities are currently ineffective 
for screening for SCLC, including computed tomog-
raphy (CT).6,7 Therefore, alternative diagnostic meth-
ods are becoming essential in order to identify SCLC 
at its earliest stages. Chest radiograph was proven to 
be ineffective after several randomized trials dem-
onstrate­no­significant­effect.8 A number of random-
ized clinical trials are currently under way in Europe 
to investigate lung cancer screening using low dose 
chest CT. Chest X-rays, chest CT scans, bone scans, 
and magnetic resonance imaging (MRI) of the brain 
have been proven effective in the staging workup of 
SCLC. Recently, positron emission tomography has 
been shown to improve staging accuracy, but none 
of these imaging modalities have played an effective 
role in screening for SCLC.
Although  modern  chest  CT  scans  are  able  to 
detect smaller solid nodules, these lesions lack spe-
cific­radiographic­features,­which­render­this­method­
incapable of differentiating the origin of the nodules.9 
However,­ certain­ nodules­ escape­ identification­ by­
chest x-ray or CT scan secondary to factors such as 
the technique used or small size of the lesion.10 The 
challenge begins with cancers that do not manifest 
preneoplastic lesions, making their detection at an ear-
lier stage (when therapeutic intervention may affect 
survival)­a­difficult,­if­not­impossible,­task.­In­a­study­
comparing the cost effectiveness of CT screening to 
smoking cessation rates or combined approaches, the 
cost-effectiveness of chest CT screening was linked 
to smoking cessation rates.11
In a recently published European study, Maison-
neuve et al found that recalibrating the Bach model to 
include nodule characteristic and size and investigat-
ing the presence of emphysema through a chest CT 
was a suitable way to select the high risk population 
for CT screening.12
The absence of characteristic changes in bronchial 
epithelium associated with SCLC creates false nega-
tive­findings­when­bronchoscopy­is­used.13­Wistuba­
et al studied surgical specimens from patients with 
different types of primary lung cancers, and signif-
icant genetic damage was found in the majority of 
patients with SCLC who had normal or mildly abnor-
mal  bronchial  epithelium  and  preserved  histologic 
examination.13,14 More recently, new means of screen-
ing for SCLC are being investigated, such as autoan-
tibody markers15 and multi-variable clinical scores.16 
Evidently, in cases of high-risk nodules, histopatho-
logic diagnosis should be considered.
Case description
A  66-year-old  Caucasian  woman  who  was  an  ex-
smoker  was  being  evaluated  as  an  outpatient  for 
  exertional shortness of breath that had worsened over 
the course of several weeks. The performed imaging 
studies included normal chest radiography and tho-
racic CT with no evidence of any parenchymal or 
mediastinal lesions as interpreted by the radiologist 
(Fig. 1). The spirometry and cardiac evaluation were 
normal. Three months after the onset of symptoms, 
the patient presented to the emergency department Small cell lung cancer doubling time
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Figure 1. Initial chest CT was interpreted as no acute pathology.
Figure 2. Chest CT scan 3 months later showing large left hilar mass of 
about 7.5 cm with mediastinal lymphadenopathy. 
note: Other CT sections showed thickening of the interlobular septa in the 
aerated portion of the left lung suggestive of lymphangitic spread of tumor.
for   worsening dyspnea, which had been occurring at 
rest for two weeks. It was associated with yellowish 
productive cough with no chills, fever, or weight loss. 
The patient denied sick contact and recent travel. The 
physical  examination  was  unremarkable  with  the 
exception of diffuse expiratory wheezing and labored 
breathing. The oxygen saturation in the room air was 
normal. A left multilobar opacity was present on the 
chest  radiography,  suggesting  pneumonia.  On  the 
fourth day of hospitalization, the patient developed 
acute respiratory failure despite intravenous steroids 
and broad-coverage antibiotics. The patient was intu-
bated and put on mechanical ventilation. Thoracic CT 
was  performed  and  revealed  several    abnormalities 
in  addition  to  the  tumorous  lesion  itself  (Fig.  2). 
There was atelectasis of the left lower lobe associated 
with­ small­ pleural­ effusion.­ Part­ of­ these­ findings­
could be secondary to obstructive pneumonia, so iden-
tifying an accurate area of cancerous lesion spreading 
is­difficult.­After­discussions­with­the­radiologist,­we­
assumed that the left hilar mass was probably between 
7  and  8  cm  with  associated  lymphangitic  spread. 
Additionally, an obstructive endobronchial mass in 
the upper and lingular left lobes was visualized and 
biopsied­using­flexible­bronchoscopy.­Findings­from­
the pathological examination of the biopsied speci-
men were indicative of SCLC. Given the initial nor-
mal chest CT, the doubling time was probably too 
rapid to preclude early detection and, therefore earlier, 
more  effective chemo-radiation therapy.  Given  her 
acute presentation and negative initial chest CT scan, 
the admission diagnosis was presumed to be severe 
pneumonia and the patient was started on intravenous 
antibiotics and other supportive measures. This man-
agement approach delayed chemo-radiation therapy 
for­about­five­days­and­the­patient­expired­a­few­days­
later from multiorgan failure.
Doubling Time of small cell  
Lung cancer
In­ some­ cases,­ SCLC­ is­ characterized­ by­ signifi-
cantly  rapid  doubling  time.  Therefore,  the  clinical 
presentation of these cancers is likely to differ from 
those  experienced  with  more  typical  cancers  and 
becomes more like an acute pulmonary manifestation, 
such­ as­ in­ an­ inflammatory­ or­ infectious­ disorder.­
Doubling time is calculated by estimating the volume 
of the nodule or tumor in two different dimensions.17 
The doubling time is usually calculated using the fol-
lowing equation: 
Ti × log 2/3 × log (Di/Do) or  
(log 2 × Ti)/(log (Vi/V o) 
where Ti = interval time, Di = initial diameter, Do =­final­
diameter, Vi = initial volume, V o =­final­volume.
Given the neuroendocrinological origin of SCLC, 
it  is  considered  the  prototype  of  rapidly  growing 
malignancies  with  doubling  time  in  the  range  of 
25 to 217 days according to several studies.10,18–20 
A­ described­ by­Wang­ et­ al,­ the­ doubling­ time­ of­
SCLC ranges from 54–132 days.9 In a study by Son 
et al, the doubling time for SCLC was 38 to 217 days 
and all patients were smokers.20 In addition, Arai, Harris et al
202  Clinical Medicine Insights: Oncology 2012:6
Kuroishi21­ used­ serial­ chest­ X-ray­ films­ to­ study­
the  doubling  time  of  lung  cancers  in  relation  to 
prognosis and found that SCLC mean doubling time 
was 86.3 days. SCLC and large cell lung cancers rep-
resented most patients in the rapidly growing cancer 
group,­which­was­defined­as­those­having­a­doubling­
time of 109.6 days. It has been noted that the rate of 
growth in the size of the lung nodules is much faster 
for malignant versus benign nodules.22 Many factors 
affect the rate of growth of these nodules, and hence 
should be taken into consideration when determining 
the frequency and type of imaging studies for follow-
up. Generally, among patients who have lung cancers 
with a rapid doubling time, SCLC had the shortest 
doubling time, followed by squamous cell carcinoma 
and  adenocarcinoma.9  Eventually,  the  histological 
subtype of the tumor as well as the smoking status 
should  be  assessed  in  order  to  make  suggestions 
concerning  follow-up.  In  instances  where  SCLC 
doubling  time  is  exceptionally  rapid,  the  clinical 
presentation can mimic other acute lung pathologies 
such as pneumonia and other acute interstitial and 
inflammatory­lung­diseases.
conclusion
Among smokers who present with acute pulmonary 
manifestations, rapidly growing SCLC can be an over-
looked diagnosis. To date, screening for SCLC is still 
an outreach. Imaging techniques for detecting SCLC 
at the curative or early stages seems to be ineffective 
and alternative methods are being investigated.
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